Help For Irritable Bowel Syndrome (IBS) - Education, Support, & Self Help for Irritable Bowel Syndrome
Heather & Company View Cart
Shop for IBSIBS Message BoardsIBS News & ReviewsStore Finder
IBS Diet & Recipes
IBS Books
IBS Supplements
Yoga for IBS
Hypnosis for IBS
Tummy Teas
Get The IBS Diet Cheat Sheet
Get Trigger Foods, Safe Foods, Ten Commandments of Eating for IBS, More!

Enter First Name:

Enter Email:

We value your privacy

All Boards >> Irritable Bowel Syndrome Research Library


Reged: 12/09/02
Posts: 7655
Loc: Seattle, WA
SOLVAY presses ahead with cilansetron, a new IBS drug
11/18/03 03:43 PM

29-10-2003 08:01:00

SOLVAY presses ahead with cilansetron registrations following favorable phase III clinical findings

SOLVAY announces today that headline results from the first two large placebo-controlled phase III efficacy studies show convincing evidence for the patient benefits of cilansetron, a novel drug developed by the Group's PHARMACEUTICALS subsidiaries for the treatment of Irritable Bowel Syndrome with predominantly diarrhea (IBS-D). In view of favorable clinical findings, SOLVAY will expedite compilation of registration dossiers for major territories, beginning with submissions in Europe and the United States in the first quarter of 2004. Registration submissions in other territories will follow.

SOLVAY is running a full phase III clinical program with cilansetron, a 5HT3 antagonist for the treatment of Irritable Bowel Syndrome with predominantly diarrhea. Together with our preferred-provider QUINTILES, more than 4,000 patients have been entered into phase III clinical studies. Cilansetron was created by SOLVAY's own in-house drug-discovery efforts. In two Phase II placebo controlled clinical studies and two Phase III placebo controlled clinical studies conducted in the US, Europe and other countries, cilansetron has shown clinical benefits in both males and females.

IBS is a frequently encountered troublesome condition, characterized by abdominal pain, bloating and altered bowel habits. IBS has a significantly negative impact on quality-of-life for the large populations of men and women suffering from it.

SOLVAY is an international chemical and pharmaceutical Group with headquarters in Brussels. It employs more than 30,000 people in 50 countries and had consolidated sales in 2002 of EUR 7.9 billion, generated by four sectors of activity: Pharmaceuticals, Chemicals, Plastics and Processing. The Group's pharmaceuticals subsidiaries employ 7500 people and have a good research and development pipeline, with several projects alongside cilansetron currently in phase III/II testing; bifeprunox for schizophrenia (together with Lundbeck), tedisamil for atrial fibrillation and cetrorelix for endometriosis, myoma and benign prostatic hypertrophy just to mention a few. SOLVAY is listed in the Euronext 100 index of top European companies. For further information please consult:

Heather is the Administrator of the IBS Message Boards. Shes the author of Eating for IBS and The First Year: IBS, and the CEO of Heather's Tummy Care. Join her IBS Newsletter. Meet Heather on Facebook!

Post Extras Print Post Remind Me! Notify Moderator

Entire thread
Subject Posted by Posted on
* Pharmaceutical HeatherAdministrator 07/14/03 01:50 PM
. * FDA approves new drug for chronic constipation HeatherAdministrator 01/26/17 03:05 PM
. * Mixed Opioid Agent Adds to Growing List of Therapies for IBS-D HeatherAdministrator 01/27/16 02:48 PM
. * Low-dose naltreoxone for the treatment of irritable bowel syndrome HeatherAdministrator 01/26/16 01:20 PM
. * Amitiza benefited patients with chronic idiopathic constipation HeatherAdministrator 02/10/15 04:15 PM
. * Medical Marijuana for Digestive Disorders: High Time to Prescribe? HeatherAdministrator 09/17/14 02:08 PM
. * Antibiotics Early in Life May Boost Obesity Risk HeatherAdministrator 08/18/14 03:13 PM
. * Antidepressants, psychological therapies effectively treated IBS HeatherAdministrator 07/15/14 02:49 PM
. * Proton pump inhibitor (acid reflux drugs) may cause heart disease HeatherAdministrator 09/23/13 03:22 PM